Navigation Links
The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
Date:3/30/2009

After the flood of layoffs in health care in January, the industry seems to have taken a deep breath and a step back, getting back on track and creating 27,000 new jobs. Health care job cuts that were announced were mostly due to the overall economic difficulty facing the United States.

(Vocus) March 30, 2009 -- While it would be irresponsible to say the worst is past for health care, it does seem as though the industry took a deep breath and a step back in February, getting back on track after January's sweeping job cuts. About 27,000 new jobs were created in health care in February -- more than 8,000 more than were created in January -- which is more in line with 2008's average monthly job increases in the 30,000 range.


   
"For the most part, health care job cuts have come as a result of increased expenses due to the current economic situation," said Michele Hopps, director of marketing for MedZilla.com, the internet's leading site for health care, biotechnology, and pharmaceutical jobs. "The bigger hit this month unfortunately came from biotech and pharmaceuticals, which have both seen difficulties over the past 18 months." While most of those companies announced layoffs in conjunction with reorganizations, strategic shifts, and other cost-cutting measures, some, such as Trubion Pharmaceuticals, said they are eliminating positions "in the face of continuing uncertainty in the capital markets and the global economy." (Puget Sound Business Journal, February 25, 2009) Hopps said that these companies often see difficulty due to the need to specialize. "They develop drugs that might fail in clinical trials or the regulatory phase, and that's a lot of money gone toward something that won't show a return on the investment."
   
Though many health systems -- including an increasing number in Canada, primarily i
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health
2. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
3. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
4. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Rabobank Releases Annual North American Food & Agribusiness Outlook
7. ViroPharma Provides 2008 Outlook
8. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
9. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
10. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
11. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Grooving down the helix 2Grooving down the helix 3Reportlinker Adds Pediatric Health Care Products and Services Report 56182 1Reportlinker Adds Pediatric Health Care Products and Services Report 56182 2Reportlinker Adds Pediatric Health Care Products and Services Report 56182 3Reportlinker Adds Pediatric Health Care Products and Services Report 56182 4Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 1Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 2Reportlinker Adds Smart Glass 3A Technologies and Global Markets Report 13840 3Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image Guided Radiosurgery for Cancer and Neurological Disorders 56175 1Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image Guided Radiosurgery for Cancer and Neurological Disorders 56175 2Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image Guided Radiosurgery for Cancer and Neurological Disorders 56175 3Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image Guided Radiosurgery for Cancer and Neurological Disorders 56175 4Doctors at Banner Good Samaritan Medical Center Now Offering Precise Image Guided Radiosurgery for Cancer and Neurological Disorders 56175 5